Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis
British Journal of Dermatology2013Vol. 170(2), pp. 415–424
Citations Over TimeTop 10% of 2013 papers
J. M. P. A. van den Reek, P.P.M. van Lümig, R.J.B. Driessen, P.C.M. van de Kerkhof, Marieke M.B. Seyger, Wietske Kievit, E.M.G.J. de Jong
Abstract
We present the longest analysis of drug survival for etanercept in psoriasis to date. Determinants of longer overall etanercept drug survival were male sex, prior anti-TNF therapy and lower etanercept dose. The determinants of longer drug survival depended on the reason for discontinuation of etanercept.
Related Papers
- → Survival Analysis: A Self-Learning Text(1997)1,358 cited
- → An Introduction to Survival Analysis(2007)90 cited
- → Kaplan-Meier and Cox proportional hazards regression in survival analysis: statistical standard and guideline of Life Cycle Committee(2023)25 cited
- → Psoriasis pustulosa, psoriasis palmoplantar, psoriasis eritrodérmica y etanercept(2010)10 cited
- → Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission(2009)5 cited